辉瑞与BioNTech SE已准备就绪,将依据美国食品药品监督管理局的建议,并在获得正式批准后,供应针对2026至2027年度的更新版新冠疫苗配方。相关计划细节载于公司提交的简报文件之中。
辉瑞与BioNTech SE已准备就绪,将依据美国食品药品监督管理局的建议,并在获得正式批准后,供应针对2026至2027年度的更新版新冠疫苗配方。相关计划细节载于公司提交的简报文件之中。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.